News & More

Global Digital Therapeutics market is valued at $3.16 Billion in 2021 and is projected to attain a value of $14.52 Billion by 2028 at a CAGR of 28.1% during the forecast period, 2022–2028. The general public has become more conscious of the continuously shifting digital scene. Furthermore, the market is fueled by rising chronic disease prevalence and rapid technology improvements. End-user awareness is predicted to rise as a result of the use of digital devices and solutions, propelling the industry forward. Consumer attitudes toward digital health are predicted to continue to alter, as will their demand for accessible, personalized, and engaging medical solutions.

The two parties will work on developing Neos, a diagnostic device for the early diagnosis of brain disorders. Neos will be integrated with the Varjo Aero headset to enable a complete, standardized, and instrument-based neuro-ophthalmologic examination using the headset's built-in VR-based eye-tracking solution. Varjo and machineMD stated that the development of Neos is advancing rapidly, with ongoing research studies at The University Hospital of Bern and several other clinics currently underway.

Now in its seventh consecutive year, the NHS-delivered programme, has supported 143 of the biggest and most effective digital innovations now being used by the NHS and social care, and many scaling globally. Examples include Huma, DrDoctor, Peppy Health, eConsult, Echo, AccuRx and HN. Over 600 additional contracts have been signed by companies during Accelerator support and the programme was also named Accelerator of the Year at the UKBAA Angel Investment Awards 2022.

Under the deal, Dawn Health will develop a platform that empowers patients and their care teams to make better and faster treatment decisions. By combining a patient mobile app focused on high engagement and exceptional UX with innovative elements like symptom tracking, novel (digital) biomarkers, clinical decision support services, virtual clinic capabilities and other relevant services as they become available - the platform will be tailored very specifically to the needs and demands of each separate disease in scope.

A hospital in Spain is launching a study to test the efficacy, tolerability, and acceptance of a drug produced for children using a 3D printer. The study results from collaboration between the Pharmacy Service at Vall d'Hebron University Hospital, the University of Santiago de Compostela, and the company FabRx. The 3D printer used for the study produces medicines in semi-solid and chewable forms, which are personalized to each child based on their weight and clinical characteristics.

Called Izar, it is an FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function. Izar is designed to fill a critical gap in neurological care today and aims to be the most effective hand dexterity and strength treatment in a wide range of neurological conditions. This proprietary peripheral is part of a comprehensive omnisite approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson's disease, Alzheimer's disease, and Traumatic Brain Injury (TBI), among others.

The new skin temperature-based cycle tracking capabilities will be available through the Samsung Health app on the Galaxy Watch5 and Watch5 Pro within the second quarter in 32 markets, which includes Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Korea, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, the U.K. and the U.S.

EPFL researchers have combined low-power chip design, machine learning algorithms, and soft implantable electrodes to produce NeuralTree, a closed-loop neuromodulation system-on-chip that can detect and alleviate symptoms of various neurological disorders.

Starting with the UK, the company now brings together Headspace's world-class meditation and mindfulness offering with on-demand coaching, therapy and EAP services to provide a single mental health solution that reduces complexity, administrative burden and cost for employers. Headspace Health plans to extend these services into additional markets throughout 2023.

In this cohort study of 11 801 patients with OUD with commercial insurance or Medicare Advantage coverage, there were no significant differences in visit frequency, initiation of medications for OUD, or OUD-related adverse outcomes between those who were treated by clinicians with high vs low telemedicine use across the prepandemic and pandemic periods.